KBC Group NV Purchases 559 Shares of Inari Medical, Inc. (NASDAQ:NARI)

KBC Group NV boosted its position in Inari Medical, Inc. (NASDAQ:NARI) by 31.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,333 shares of the company’s stock after purchasing an additional 559 shares during the quarter. KBC Group NV’s holdings in Inari Medical were worth $119,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after acquiring an additional 473 shares in the last quarter. Covestor Ltd grew its holdings in Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after purchasing an additional 926 shares during the period. Values First Advisors Inc. purchased a new stake in Inari Medical in the third quarter worth about $128,000. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Inari Medical by 44.2% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock valued at $128,000 after purchasing an additional 954 shares in the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of Inari Medical by 84.6% during the third quarter. Quest Partners LLC now owns 4,051 shares of the company’s stock valued at $167,000 after purchasing an additional 1,856 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on NARI shares. Robert W. Baird restated a “neutral” rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $80.00 price target (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Piper Sandler upped their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $80.00 price objective (up from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Inari Medical presently has an average rating of “Hold” and a consensus price target of $68.00.

Inari Medical Price Performance

NASDAQ NARI opened at $79.76 on Friday. The stock has a market capitalization of $4.67 billion, a price-to-earnings ratio of -59.08 and a beta of 1.02. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $79.93. The business’s fifty day moving average price is $65.69 and its 200-day moving average price is $53.26.

Insiders Place Their Bets

In other news, Director William Hoffman sold 60,000 shares of Inari Medical stock in a transaction on Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the transaction, the director now owns 501,233 shares in the company, valued at $25,643,080.28. This trade represents a 10.69 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the sale, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 323,000 shares of company stock valued at $18,669,070. Insiders own 10.60% of the company’s stock.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.